tiprankstipranks
Trending News
More News >
NOVARESE,Inc. (JP:9160)
:9160
Japanese Market

NOVARESE,Inc. (9160) AI Stock Analysis

Compare
0 Followers

Top Page

JP:9160

NOVARESE,Inc.

(9160)

Select Model
Select Model
Select Model
Neutral 65 (OpenAI - 5.2)
Rating:65Neutral
Price Target:
¥344.00
▲(9.90% Upside)
Action:DowngradedDate:02/18/26
The score is driven primarily by improving financial performance (recovery in revenue and profitability) but constrained by still-elevated leverage and a recent decline in free cash flow. Valuation is a positive contributor due to the low P/E, while technicals are mixed with negative MACD and the price sitting below key longer-term moving averages.
Positive Factors
Revenue recovery
Sustained revenue growth through 2025 demonstrates the company has regained demand traction since the 2020 trough. A rising top line provides a firmer base for operating leverage, supports reinvestment in products and services, and reduces reliance on one-off gains for earnings stability.
Improving profitability
Higher operating and net margins in 2025 point to better cost control and pricing execution. Durable margin improvement, if maintained, strengthens cash flow generation potential and the ability to reinvest in automation capabilities, improving long-term competitive positioning.
Positive cash generation
Consistent positive operating and free cash flow since the turnaround supports internal funding for capex and working capital, lowering dependence on external financing. The move from negative to positive cash flow indicates structural improvement in business economics and liquidity resilience.
Negative Factors
Elevated leverage
A debt-heavy capital structure (debt > equity, D/E ~1.22x) constrains financial flexibility, raising refinancing and interest-rate risk. Elevated leverage limits the company's ability to pursue opportunistic investments or absorb cyclical downturns without increasing financial strain.
Weaker cash conversion
Declining free cash flow and FCF below net income suggest working capital or capex pressures and weaker earnings-to-cash conversion. If persistent, this reduces capacity to pay down debt, fund growth organically, or sustain distributions, increasing reliance on external financing.
Margin volatility
Notable margin swings versus the 2022 high indicate earnings are sensitive to cost or mix shifts. Ongoing margin volatility undermines predictability of profits, complicates strategic planning and valuation of long-term returns, and may reflect exposure to cyclical industrial demand or pricing pressure.

NOVARESE,Inc. (9160) vs. iShares MSCI Japan ETF (EWJ)

NOVARESE,Inc. Business Overview & Revenue Model

Company DescriptionNovarese, Inc. engages in the wedding and restaurant businesses in Japan and internationally. The company provides wedding-related services, including venue guidance, wedding day planning, food and gift selection, and day-of operations; operates dress shops under the NOVARESE and ECRUSPOSE brands, that sells and rents wedding dresses, tuxedos, and Japanese attire, as well as party dresses for wedding and reception attendees; operates wedding banquets and restaurants; and provides flower decoration, as well as photography and videography services for weddings, and other events and parties. It also involved in the operation of WEDO, system that supports marriage preparation; provision of gifts to bride, groom, and guests at the wedding reception; business support services; and advertising agency services, including advertising planning, visual photography, graphic design, production of promotional tools, media purchasing, and planning and management of PR events. The company was formerly known as Workaholic Co., Ltd. and changed its name to Novarese, Inc. in December 2002. Novarese, Inc. was founded in 2000 and is headquartered in Chuo, Japan.
How the Company Makes MoneyNOVARESE, Inc. generates revenue primarily through the sale of its proprietary therapeutic products and diagnostic services. The company has established key revenue streams from direct product sales to healthcare providers and institutions, as well as licensing agreements with pharmaceutical companies for its patented technologies. Additionally, NOVARESE engages in strategic partnerships with research organizations and healthcare systems, which not only enhances its research capabilities but also opens up new markets and distribution channels. Government grants and funding for research initiatives also contribute to the company's financial health, allowing for sustained innovation and development.

NOVARESE,Inc. Financial Statement Overview

Summary
Improving operating results and steady revenue growth (2025 revenue up ~5.3% YoY) support the score, but earnings quality is tempered by margin volatility versus the 2022 peak. The balance sheet is gradually de-risking, yet leverage remains elevated (2025 debt-to-equity ~1.22x). Cash flow is positive, though 2025 free cash flow declined (~-13.8% YoY) and trails net income, indicating weaker cash conversion.
Income Statement
72
Positive
Revenue has rebounded strongly from 2020 and continued to grow through 2025 (2025 revenue up ~5.3% year over year). Profitability also improved versus 2024, with higher operating and net margins in 2025. However, margins are still well below the 2022 peak (notably net margin and operating margin), highlighting some volatility in underlying earnings power.
Balance Sheet
58
Neutral
Leverage remains elevated, with debt still exceeding equity (2025 debt-to-equity ~1.22x), which can limit flexibility in a downturn. The good news is the balance sheet has been de-risking versus prior years (debt-to-equity fell materially from 2021–2023 levels), supported by a growing equity base. Overall asset size is stable, but the capital structure is still meaningfully debt-heavy.
Cash Flow
64
Positive
Cash generation is solid: 2025 operating cash flow and free cash flow are both positive and sizable. That said, free cash flow declined in 2025 (about -13.8% year over year), and free cash flow is less than net income in 2025, suggesting weaker cash conversion than some prior years. The company has improved significantly from 2020’s negative cash flow, but cash flow consistency remains a watch item.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue22.04B19.30B18.27B17.22B11.19B
Gross Profit12.24B10.86B10.18B10.14B6.40B
EBITDA4.73B3.82B3.91B4.93B2.93B
Net Income1.26B663.90M942.27M1.66B374.02M
Balance Sheet
Total Assets36.82B34.73B32.30B31.98B32.63B
Cash, Cash Equivalents and Short-Term Investments3.42B3.57B1.72B2.80B2.25B
Total Debt12.37B13.53B19.01B14.13B22.31B
Total Liabilities26.71B25.89B24.12B24.75B27.04B
Stockholders Equity10.11B8.85B8.18B7.23B5.59B
Cash Flow
Free Cash Flow2.27B2.50B1.02B3.26B2.15B
Operating Cash Flow4.76B3.89B3.00B4.62B2.37B
Investing Cash Flow-2.65B-1.45B-2.03B-1.34B-253.64M
Financing Cash Flow-2.22B-621.47M-2.04B-2.73B-2.21B

NOVARESE,Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price313.00
Price Trends
50DMA
314.42
Negative
100DMA
325.25
Negative
200DMA
323.01
Negative
Market Momentum
MACD
-0.45
Positive
RSI
35.88
Neutral
STOCH
14.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9160, the sentiment is Negative. The current price of 313 is below the 20-day moving average (MA) of 313.75, below the 50-day MA of 314.42, and below the 200-day MA of 323.01, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 35.88 is Neutral, neither overbought nor oversold. The STOCH value of 14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9160.

NOVARESE,Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
¥24.03B3.593.04%-3.47%14.42%
69
Neutral
¥10.32B5.245.06%0.36%81.58%
69
Neutral
¥3.45B-6.021.24%6.77%40.10%
65
Neutral
¥7.57B6.2412.19%28.25%
64
Neutral
¥11.70B12.724.02%14.46%18.48%
61
Neutral
$18.38B12.79-2.54%3.03%1.52%-15.83%
54
Neutral
¥3.80B3.91-4.35%-132.57%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:9160
NOVARESE,Inc.
302.00
4.00
1.34%
JP:2196
ESCRIT Inc.
159.00
-41.00
-20.50%
JP:2198
IKK Holdings Co., Ltd
809.00
-7.89
-0.97%
JP:2424
Brass Corp.
606.00
47.38
8.48%
JP:2485
TEAR Corp.
520.00
74.67
16.77%
JP:4331
Take and Give. Needs Co., Ltd.
710.00
-179.07
-20.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 18, 2026